Quadrichemotherapy for advanced ovarian carcinoma

Area of Science:

• Oncology
• Medical Research

Background:

• Advanced ovarian carcinoma presents challenges in treatment efficacy.
• Improving objective response rates and duration is a key therapeutic goal.

Purpose of the Study:

• To evaluate a four-drug combination chemotherapy regimen for advanced ovarian carcinoma.
• To assess the objective response rate, duration, and survival in patients with FIGO Stage III and IV disease.

Main Methods:

• A combination of vincristine, actinomycin D, methotrexate, and cyclophosphamide was administered to 25 evaluable patients.
• Treatment involved weekly intravenous vincristine and actinomycin D, with daily oral methotrexate and cyclophosphamide.
• Vincristine and initial methotrexate were discontinued after 12 weeks; cyclophosphamide and methotrexate continued until progression.

Main Results:

• An objective response rate of 56% was observed in the patient cohort.
• Complete response rates were higher in previously untreated patients (30%) compared to previously treated patients (13.3%).
• Mean complete response duration was 10.6+ months, with 1-year and 5-year survival rates of 69.5% and 22.7%, respectively. Minimal toxicity was reported.

Conclusions:

• The four-drug combination demonstrated encouraging objective response rates and survival data in advanced ovarian carcinoma.
• The regimen's efficacy appears comparable to single-agent chemotherapy with an alkylating agent.
• Further research may be warranted to optimize combination strategies or compare against standard single-agent therapies.